310 related articles for article (PubMed ID: 8698875)
41. Presence of a population of CD20+, CD38- B lymphocytes with defective proliferative responsiveness in the synovial compartment of patients with rheumatoid arthritis.
Reparon-Schuijt CC; van Esch WJ; van Kooten C; Ezendam NP; Levarht EW; Breedveld FC; Verweij CL
Arthritis Rheum; 2001 Sep; 44(9):2029-37. PubMed ID: 11592364
[TBL] [Abstract][Full Text] [Related]
42. The role of CD40 ligand in systemic lupus erythematosus.
Yazdany J; Davis J
Lupus; 2004; 13(5):377-80. PubMed ID: 15230296
[TBL] [Abstract][Full Text] [Related]
43. Phoenix from the flames: Rediscovering the role of the CD40-CD40L pathway in systemic lupus erythematosus and lupus nephritis.
Ramanujam M; Steffgen J; Visvanathan S; Mohan C; Fine JS; Putterman C
Autoimmun Rev; 2020 Nov; 19(11):102668. PubMed ID: 32942031
[TBL] [Abstract][Full Text] [Related]
44. Increased frequency of circulating follicular helper T cells in lupus patients is associated with autoantibody production in a CD40L-dependent manner.
Xu H; Liu J; Cui X; Zuo Y; Zhang Z; Li Y; Tao R; Li Y; Pang J
Cell Immunol; 2015 May; 295(1):46-51. PubMed ID: 25748125
[TBL] [Abstract][Full Text] [Related]
45. Distinct roles of ICOS and CD40L in human T-B cell adhesion and antibody production.
Liu Z; Liu S; Zhang Y; Zeng W; Wang S; Ji P; Pan M; Zhu C; Wang Y
Cell Immunol; 2021 Oct; 368():104420. PubMed ID: 34418679
[TBL] [Abstract][Full Text] [Related]
46. The ability of CD4+ cells from HIV+ individuals to express CD40 ligand after in vitro stimulation is not impaired.
Brugnoni D; Prati E; Airò P; Castelli F; Cattaneo R
Clin Immunol Immunopathol; 1995 Jan; 74(1):112-4. PubMed ID: 7994920
[TBL] [Abstract][Full Text] [Related]
47. Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7.
Nakajima A; Kodama T; Morimoto S; Azuma M; Takeda K; Oshima H; Yoshino S; Yagita H; Okumura K
J Immunol; 1998 Aug; 161(4):1901-7. PubMed ID: 9712059
[TBL] [Abstract][Full Text] [Related]
48. Decreased expression of the ligand for CD40 in newborn lymphocytes.
Fuleihan R; Ahern D; Geha RS
Eur J Immunol; 1994 Aug; 24(8):1925-8. PubMed ID: 7914491
[TBL] [Abstract][Full Text] [Related]
49. Cytotoxicity and weak CD40 ligand expression of CD8+ type 2 cytotoxic T cells restricts their potential B cell helper activity.
Sad S; Krishnan L; Bleackley RC; Kägi D; Hengartner H; Mosmann TR
Eur J Immunol; 1997 Apr; 27(4):914-22. PubMed ID: 9130644
[TBL] [Abstract][Full Text] [Related]
50. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.
Tokunaga M; Fujii K; Saito K; Nakayamada S; Tsujimura S; Nawata M; Tanaka Y
Rheumatology (Oxford); 2005 Feb; 44(2):176-82. PubMed ID: 15494350
[TBL] [Abstract][Full Text] [Related]
51. Modulation of CD40L antigen expression in Jurkat cells: involvement of protein kinase C activity.
Lisowska K; Bryl E; Soroczyńska M; Witkowski JM
Folia Histochem Cytobiol; 2003; 41(4):233-5. PubMed ID: 14677764
[TBL] [Abstract][Full Text] [Related]
52. Evidence for a critical role for IL-2 in CD40-mediated activation of naive B cells by primary CD4 T cells.
Johnson-Léger C; Christenson JR; Holman M; Klaus GG
J Immunol; 1998 Nov; 161(9):4618-26. PubMed ID: 9794390
[TBL] [Abstract][Full Text] [Related]
53. Activated B cells express CD28/B7-independent costimulatory activity.
Ding L; Shevach EM
J Immunol; 1996 Aug; 157(4):1389-96. PubMed ID: 8759718
[TBL] [Abstract][Full Text] [Related]
54. Impaired suppressive capacity of activation-induced regulatory B cells in systemic lupus erythematosus.
Gao N; Dresel J; Eckstein V; Gellert R; Störch H; Venigalla RK; Schwenger V; Max R; Blank N; Lorenz HM; Tretter T
Arthritis Rheumatol; 2014 Oct; 66(10):2849-61. PubMed ID: 24942956
[TBL] [Abstract][Full Text] [Related]
55. CD40 expressed on thymic epithelial cells provides costimulation for proliferation but not for apoptosis of human thymocytes.
Ruggiero G; Martinez Cáceres E; Voordouw A; Noteboom E; Graf D; Kroczek RA; Spits H
J Immunol; 1996 May; 156(10):3737-46. PubMed ID: 8621909
[TBL] [Abstract][Full Text] [Related]
56. Phorbol myristate acetate (PMA) reverses inhibition of interleukin-2 production by T lymphocytes of patients with systemic lupus erythematosus.
Sierakowski S; Kucharz EJ
Med Interne; 1988; 26(1):67-73. PubMed ID: 3261032
[TBL] [Abstract][Full Text] [Related]
57. Expression of CD40/CD40 ligand and Bcl-2 family proteins in labial salivary glands of patients with Sjögren's syndrome.
Nakamura H; Kawakami A; Tominaga M; Migita K; Kawabe Y; Nakamura T; Eguchi K
Lab Invest; 1999 Mar; 79(3):261-9. PubMed ID: 10092062
[TBL] [Abstract][Full Text] [Related]
58. The soluble CD40 ligand sCD154 in systemic lupus erythematosus.
Kato K; Santana-Sahagún E; Rassenti LZ; Weisman MH; Tamura N; Kobayashi S; Hashimoto H; Kipps TJ
J Clin Invest; 1999 Oct; 104(7):947-55. PubMed ID: 10510335
[TBL] [Abstract][Full Text] [Related]
59. CD40-CD40 ligand interactions stimulate B cell antigen processing.
Faassen AE; Dalke DP; Berton MT; Warren WD; Pierce SK
Eur J Immunol; 1995 Dec; 25(12):3249-55. PubMed ID: 8566008
[TBL] [Abstract][Full Text] [Related]
60. Accessory signaling by CD40 for T cell activation: induction of Th1 and Th2 cytokines and synergy with interleukin-12 for interferon-gamma production.
Peng X; Kasran A; Warmerdam PA; de Boer M; Ceuppens JL
Eur J Immunol; 1996 Jul; 26(7):1621-7. PubMed ID: 8766570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
